Eyenovia (NASDAQ:EYEN) Releases Earnings Results, Beats Expectations By $5.61 EPS

Eyenovia (NASDAQ:EYEN) released its earnings results on Monday. The company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.20) by $5.61, Zacks reports. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%.

Eyenovia Price Performance

Shares of EYEN remained flat at $1.13 during mid-day trading on Monday. 2,021,096 shares of the company were exchanged, compared to its average volume of 170,692. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. Eyenovia has a 12-month low of $0.85 and a 12-month high of $124.80. The company has a 50-day moving average of $1.18 and a two-hundred day moving average of $6.23. The stock has a market capitalization of $3.20 million, a price-to-earnings ratio of -0.02 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 target price on shares of Eyenovia in a report on Friday, March 21st.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.